Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease (IBD) – UC ...

Psilocybin, a psychedelic compound found in certain mushrooms, could offer a more cost-effective treatment option for major depressive disorder than current methods, according to research from ...

Generative AI (GenAI) technology is already transforming everyday regulatory and safety processes, thanks to its ability to digest, assess, and summarise key insights and findings from across vast ...

The pharmaceutical industry is among the most heavily regulated in the world – and with increased globalisation and the enhanced understanding of risk, regulation requirements will continue to grow.

Swedish pharma company Vicore has won breakthrough status from the FDA for Almee, a cognitive behavioural therapy (CBT) app used to support people with pulmonary fibrosis (PF). Almee takes the ...

The 21st century pharmaceutical and biotech sector has come a long way from its roots in 19th century pharmacy. pharmaphorum looks at its evolution over the centuries. The roots of the ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Orphan drugs are designed to treat rare diseases, but “rare” is a relative term. Each individual drug approved for an orphan disease could be relevant for as many as 200,000 people. Worldwide ...

The Federal Trade Commission (FTC) has sued the top three pharmacy benefit managers (PBMs) in the US for operating a "perverse drug rebate system" that it claims artificially inflated the prices ...

Philip Morris International (PMI) is selling inhaled drug specialist Vectura to Molex Asia Holdings for a fraction of the £1.1 billion ($1.45 billion) it paid for the business three years ago.

GSK and other drugmakers fending off litigation claiming that gastrointestinal drug Zantac or a generic caused cancer have won a supreme court ruling in Canada, after also chalking up wins in the US.